share_log

Organigram Reports 262% Higher Quarterly Net Loss YoY, Makes Progress In International Markets

Organigram Reports 262% Higher Quarterly Net Loss YoY, Makes Progress In International Markets

Organigram報告稱,季度淨虧損同比增長262%,國際市場取得進展
Benzinga ·  05/14 19:12

Canadian cannabis company Organigram Holdings Inc.(NASDAQ:OGI) (TSX:OGI) reported its financial results Tuesday for the second quarter that ended March 31, 2024, revealing net revenue of CA$37.63 million ($27.53 million), compared to CA$39.5 million in the same period of last year.

加拿大大麻公司Organigram Holdings Inc.(納斯達克股票代碼:OGI)(多倫多證券交易所股票代碼:OGI)週二公佈了截至2024年3月31日的第二季度財務業績,淨收入爲3763萬加元(合2753萬美元),而去年同期爲3,950萬加元。

"We are pleased with our performance against the strategic priorities we laid out at the beginning of Fiscal 2024," stated CEO Beena Goldenberg. "Organigram is now the only licensed producer among the top three licensed producers in Canada with significant cash, negligible debt, and sizeable funds earmarked for strategic international investment. We have also made solid progress toward our goal of diversifying our exposure to international markets through our Jupiter fund and increasing our customer base abroad. Domestically, we grew our market share throughout Q2 Fiscal 2024 and we remain focused on driving additional gains in the back half of Fiscal 2024 by expanding distribution, introducing new products, and executing high-impact retail campaigns."

首席執行官比娜·戈登伯格表示:“我們對我們在2024財年初制定的戰略優先事項方面的表現感到滿意。”“Organigram現在是加拿大前三大持牌生產商中唯一一家擁有大量現金、微不足道的債務和大量專用於戰略國際投資的資金的持牌生產商。我們在實現通過木星基金分散國際市場敞口和增加海外客戶群的目標方面也取得了穩步進展。在國內,我們在2024財年第二季度增長了市場份額,我們將繼續專注於通過擴大分銷、推出新產品和開展高影響力的零售活動來推動2024財年後半年的額外收益。”

More about investments and financial data from the industry you can hear at the 19th Benzinga Cannabis Capital Conference in Chicago this October 8-9. Engage with top executives, investors, policymakers, and advocates to explore the industry's future. Secure your tickets now before prices increase by following this link.

您可以在10月8日至9日在芝加哥舉行的第19屆Benzinga大麻資本會議上聽到有關該行業投資和財務數據的更多信息。與高層管理人員、投資者、政策制定者和倡導者互動,探索該行業的未來。在價格上漲之前,立即通過以下方式保護您的門票 這個鏈接

Fiscal Q2 Financial Summary

第二財季財務摘要

  • Net loss amounted to CA$27.08 million, a 262% change from net loss of CA$7.49 million in the same period of 2023. The increase in net loss from the comparative period, the company attributed primarily to lower unrealized gain on changes in the fair value of biological assets and change in fair value of derivative liabilities of $12.5 million.
  • Adjusted EBITDA was a loss of CA$1.05 million, versus an adjusted EBITDA gain of CA$5.65 million in the corresponding period of last year.
  • The gross margin before fair value changes to biological assets, inventories sold, and other charges was CA$11.26 million, which compares to a gross margin of CA$9.85 million in the second fiscal quarter of 2023.
  • Selling (including marketing), general & administrative expenses grew 25% year-over-year to CA$20.16 million.
  • Cost of sales decreased to CA$26.4 million, from CA$29.6 million in the same period of 2023, primarily due to higher inventory provisions in the second fiscal quarter of 2023 of CA$3.2 million related to net realizable value adjustments of inventories
  • On March 31, 2024, the company had cash (restricted & unrestricted) of $83.6 million.
  • 淨虧損爲2708萬加元,較2023年同期的749萬加元淨虧損增長262%。與比較期相比,該公司淨虧損的增加主要歸因於生物資產公允價值變動的未實現收益減少以及衍生負債公允價值變動1,250萬美元。
  • 調整後的息稅折舊攤銷前利潤爲虧損105萬加元,而去年同期調整後的息稅折舊攤銷前利潤收益爲565萬加元。
  • 扣除生物資產、出售庫存和其他費用的公允價值變動前的毛利率爲1126萬加元,而2023年第二財季的毛利率爲985萬加元。
  • 銷售(包括營銷)、一般和管理費用同比增長25%,達到2,016萬加元。
  • 銷售成本從2023年同期的2960萬加元降至2640萬加元,這主要是由於2023年第二財季與庫存可變現淨值調整相關的庫存準備金增加了320萬加元
  • 2024年3月31日,該公司的現金(限制性和非限制性)爲8,360萬美元。

OGI Price Action

OGI 價格走勢

Organigram shares traded flat at $1.84 per share during Tuesday's pre-market session.

在週二的盤前交易中,Organigram股價持平至每股1.84美元。

Photo: Courtesy of ShutterstockProfessional via Shutterstock

照片:由 ShutterstockProfessional 通過 Shutterstock 提供

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論